A detailed history of Black Rock Inc. transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Black Rock Inc. holds 486,967 shares of PDSB stock, worth $798,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
486,967
Previous 1,867,427 73.92%
Holding current value
$798,625
Previous $7.4 Million 80.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.55 - $4.02 $3.52 Million - $5.55 Million
-1,380,460 Reduced 73.92%
486,967 $1.43 Million
Q1 2024

May 10, 2024

SELL
$3.85 - $6.59 $53,942 - $92,332
-14,011 Reduced 0.74%
1,867,427 $7.4 Million
Q4 2023

Feb 13, 2024

BUY
$3.95 - $6.58 $307,922 - $512,943
77,955 Added 4.32%
1,881,438 $9.35 Million
Q3 2023

Nov 13, 2023

BUY
$4.8 - $6.4 $338,712 - $451,616
70,565 Added 4.07%
1,803,483 $9.11 Million
Q2 2023

Aug 11, 2023

BUY
$5.03 - $9.9 $6.4 Million - $12.6 Million
1,272,801 Added 276.63%
1,732,918 $8.72 Million
Q1 2023

May 12, 2023

BUY
$5.68 - $11.99 $44,020 - $92,922
7,750 Added 1.71%
460,117 $2.83 Million
Q4 2022

Feb 13, 2023

SELL
$3.28 - $13.2 $60,128 - $241,982
-18,332 Reduced 3.89%
452,367 $5.97 Million
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.79 $4,119 - $8,030
-1,387 Reduced 0.29%
470,699 $1.4 Million
Q2 2022

Aug 12, 2022

BUY
$3.05 - $6.68 $111,270 - $243,699
36,482 Added 8.38%
472,086 $1.72 Million
Q1 2022

May 12, 2022

BUY
$4.78 - $8.43 $20,071 - $35,397
4,199 Added 0.97%
435,604 $2.7 Million
Q4 2021

Feb 10, 2022

BUY
$7.76 - $14.35 $17,281 - $31,957
2,227 Added 0.52%
431,405 $3.5 Million
Q3 2021

Nov 09, 2021

BUY
$9.33 - $17.08 $258,963 - $474,072
27,756 Added 6.91%
429,178 $6.4 Million
Q2 2021

Aug 11, 2021

BUY
$4.35 - $12.86 $1.75 Million - $5.16 Million
401,422 New
401,422 $5.04 Million

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $46.7M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.